Circular Genomics
Albuquerque
About Circular Genomics
Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predicts whether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $28.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: circulargenomics.com
Industries & Categories
Biotechnology, Health Care, Neuroscience, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/circular-genomics-4772 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.